What sarcopenia means
Researchers describe sarcopenia as the age-related loss of muscle or lean mass. Others define it as the loss of muscle mass and strength together.
How one expert group approached diagnosis
In 2014 the Asian Working Group for Sarcopenia (AWGS) defined sarcopenia as age-related loss of muscle mass, plus low muscle strength, and/or low physical performance. Its 2019 consensus, published in 2020 with criteria written for Asian populations, kept that definition but revised the diagnostic steps, the measurement protocols and some criteria. The 2019 consensus treated skeletal muscle strength and mass as both fundamental to a definitive clinical diagnosis.
The AWGS 2025 consensus updates the Asia-specific framework: simultaneous low muscle mass and low muscle strength are required for diagnosis, while physical performance is considered an outcome. The guidance also extends proposed diagnostic criteria to adults aged 50–64. These are clinical criteria, not Systematic Healthspan Assessment standards.
The 2019 consensus also added a category called possible sarcopenia, meaning low muscle strength or low physical performance on its own. It is meant for primary care and community health programs, so that people can be identified earlier and lifestyle changes can start sooner.
Screening cutoffs, and why the numbers vary
As an example, the 2019 AWGS consensus starts screening with any one of these: a calf circumference under 34 cm in men or under 33 cm in women (centimeters are the study's unit), a SARC-F questionnaire score of 4 or more, or a SARC-CalF score of 11 or more.
These are clinical screening cutoffs for Asian populations. None of them is a Systematic standard, and the Systematic assessment does not screen for or diagnose sarcopenia.
A single diagnostic criterion has not yet been established. A 2022 review of global prevalence found that studies differed a great deal because of the diagnostic criteria they used and the populations they studied. Depending on the classification and cutoff, the prevalence of sarcopenia ranged from 10% to 27% in the studies it pooled, so no one figure applies to everyone.
The evidence
Each cited source is labeled according to how it supports the particular claim on this page. Direct test evidence, underlying-capacity findings and population reference values are distinguished from Systematic-defined protocols and standards. Historical development notes are retained internally rather than presented as public evidence. A study of an underlying capacity is never presented as validation of the Systematic test itself.
-
Underlying-capacity evidence New source
Mitchell et al. (2012). Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Frontiers in physiology.
What it found. The review describes sarcopenia as the age-related loss of muscle or lean mass.
What it does not show. It gives no screening cutoffs and no single prevalence figure.
-
Underlying-capacity evidence New source
Chen et al. (2020). Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association.
What it found. The 2019 AWGS consensus (published 2020, criteria for Asian populations) kept the earlier definition, revised the diagnostic steps, kept strength and mass as fundamental to diagnosis, added possible sarcopenia, and set screening cutoffs for earlier identification.
What it does not show. It is the dated 2019 guidance, since updated by a newer AWGS consensus, and its clinical cutoffs are not Systematic standards.
-
Underlying-capacity evidence New source
Chen et al. (2025). A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nature aging.
What it found. The 2025 AWGS consensus requires concurrent low muscle mass and low muscle strength for diagnosis, treats physical performance as an outcome, and extends diagnosis to adults aged 50 to 64.
What it does not show. These are clinical criteria for Asian populations, not Systematic Healthspan Assessment standards, and it gives no Systematic diagnosis.
-
Underlying-capacity evidence New source
Petermann-Rocha et al. (2022). Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle.
What it found. No single diagnostic criterion exists yet. Prevalence varied considerably, from 10% to 27% in the pooled studies, depending on the classification and cutoff used and the population studied.
What it does not show. It gives no universal prevalence for every population and no individual likelihood from a Systematic score.
The Systematic Healthspan Assessment is a physical baseline. It is not a diagnosis, and it does not estimate a biological age, a disease risk or a lifespan.